Straits Times Index
3,078.86 +12.92 (+0.42%) Nikkei
33,450.32 +41.93 (+0.13%) Hang Seng
17,049.41 -304.73 (-1.76%) FTSE 100
7,455.24 -5.46 (-0.07%) Bitcoin USD
37,975.43 +825.44 (+2.22%) CMC Crypto 200
785.29 +20.60 (+2.69%)
Orion Oyj (ORINF)
| Previous close | 38.38 |
| Open | 38.38 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 38.38 - 38.38 |
| 52-week range | 37.00 - 46.65 |
| Volume | |
| Avg. volume | 67 |
| Market cap | 5.625B |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | 28.22 |
| EPS (TTM) | 1.36 |
| Earnings date | N/A |
| Forward dividend & yield | 1.74 (4.55%) |
| Ex-dividend date | 23 Mar 2023 |
| 1y target est | N/A |
- GlobeNewswire
Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov database
ORION CORPORATION INVESTOR NEWS 21 NOVEMBER 2023 at 08:30 EET Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov database Two new Phase 3 clinical trials to evaluate the safety and efficacy of ODM-208 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) have been posted to the ClinicalTrials.gov website. The studies are not yet recruiting patients. Further information is available on ClinicalTrials.gov A study of MK-5684 Versus Alter
- GlobeNewswire
Orion Animal Health receives FDA approval for Bonqat® (pregabalin oral solution)
ORION CORPORATION PRESS RELEASE 20 NOVEMBER 2023 at 15.00 EET Orion Animal Health receives FDA approval for Bonqat® (pregabalin oral solution) Orion Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Bonqat® (pregabalin oral solution) for alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats. Pregabalin is a new active substance for veterinary use and it acts in the central nervous system by reducing t
- GlobeNewswire
Orion Corporation: Managers’ transactions – Agendum Oy
ORION CORPORATION MANAGERS’ TRANSACTIONS 16 NOVEMBER 2023 at 10.15 EET Orion Corporation: Managers’ transactions – Agendum Oy Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Agendum
